On January 20, Johnson & Johnson (NYSE:JNJ) announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%. International sales decreased 6.7%, reflecting operational growth of 1.2% and a negative currency impact of 7.9%.On Wednesday shares of Johnson & Johnson (NYSE:JNJ) closed at $101.36. Company’s sales growth for last 5 years was 3.70% and EPS growth for next 5 years is recorded as 5.46%.
Brazil’s state-controlled oil company Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR-A) provided the names of the five top executives who resigned along with Chief Executive Maria das Graças Foster. Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR-A) in last trading activity moved down -0.67% to close at $7.39. Company weekly performance is 6.48% while its quarterly performance stands at -36.68%. Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR-A) is -66.62% away from its 52 week high.
Foresight Energy LP (NYSE:FELP) had its target price decreased by Citigroup Inc. from $24.00 to $21.00 in a report issued on Tuesday. They currently have a buy rating on the stock. On last trading day Foresight Energy LP (NYSE:FELP) moved down -0.57% to close at $15.75. Its volatility for the week is 5.73% while volatility for the month is 4.13%. FELP’s sales growth for past 5 years was 32.00% and its EPS growth for past 5 years was -29.30%. Foresight Energy LP (NYSE:FELP) monthly performance is -2.78%.
SunEdison, Inc. (NYSE:SUNE) has announced the commissioning of a 7.72 MW solar power plant that will generate clean electricity for Brakes India Limited (BIL). Brakes India Limited was established in 1962 and is the nation’s leading manufacturer of automotive and non-automotive braking systems and ferrous castings. On Wednesday shares of SunEdison, Inc. (NYSE:SUNE) closed at $20.02. Company’s EPS growth for next 5 years is recorded as 1.58%.
Eli Lilly and Company (NYSE:LLY) and partner Boehringer Ingelheim have gained FDA approval for Glyxambi (Jardiance/Tradjenta) tablets for use as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes when treatment with both Jardiance and Tradjenta are considered appropriate. Eli Lilly and Company (NYSE:LLY) in last trading activity fell -0.95% to close at $70.22. Company weekly performance is -1.06% while its quarterly performance stands at 6.30%. Eli Lilly and Company (NYSE:LLY) is -6.50% away from its 52 week high.